Articles From: Redknee Wins Light Reading Leading Lights Inaugural Outstanding OSS/BSS Vendor of the Year Award to Regal Entertainment Group Announces Timing of Fiscal Second Quarter 2014 Earnings Release and Conference Call


2014/6/18
Redknee Wins Light Reading Leading Lights Inaugural Outstanding OSS/BSS Vendor of the Year Award Canada NewsWire Ray Le Maistre, Editor-in-Chief, Light Reading commented: "The standard of the entries in all 16 Leading Lights categories this year was exceptionally high, so the winners have really had to prove themselves worthy with great submissions that have been able to stand up to thorough scrutiny.
Sign-up for Redknee Wins Light Reading Leading Lights Inaugural Outstanding OSS/BSS Vendor of the Year Award investment picks
Redline Communications Acquires PureWave Networks Assets Canada NewsWire Acquisition Increases Breadth of Redline's Technology and Patent Portfolio TORONTO , Sept.
Sign-up for Redline Communications Acquires PureWave Networks Assets investment picks
Redline Communications Announces Election of Directors Canada NewsWire TORONTO , June 28, 2014 /CNW/ - Redline Communications ( www.rdlcom.com ) Group Inc.( TSX: RDL ), a leading provider of mission critical wireless networks for the oil and gas industry, today announced that all of management's nominees listed in the management proxy circular of Redline Communications dated May 27, 2014 , 2014 were elected as directors of Redline to hold office until the next annual meeting of shareholders of Redline or until their successors are elected or appointed.
Sign-up for Redline Communications Announces Election of Directors investment picks
2014/7/22
Redline Q2-2014 Conference Call Notice Canada NewsWire TORONTO , July 22, 2014 /CNW/ - Redline Communications ( www.rdlcom.com Group Inc. TSX: RDL ) a leading provider of mission-critical wireless networks will release financial results for its second quarter ended June 30, 2014 following the close of trading on the Toronto Stock Exchange August 12, 2014.
Sign-up for Redline Q2-2014 Conference Call Notice investment picks
2014/8/6
http://media.marketwire.com/attachments/201401/218602_RedPoint-Logo-Standard-Fina.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1136069&ProfileId=051205&sourceType=1 WELLESLEY HILLS, MA --
Sign-up for RedPoint Global Closes $5.2 Million Financing Led by Grotech Ventures investment picks
New Redtail CRM User Interface Incorporates Morningstar's Proprietary Research and Analytics GOLD RIVER, Calif.
Sign-up for Redtail Technology and Morningstar Work Together to Simplify Advisor Practice through Redtail's Enhanced CRM User Interface investment picks
NIWeek : NI (Nasdaq: NATI), the provider of solutions that enable engineers and scientists to solve the world’s greatest engineering challenges, today announced the CompactDAQ 4-slot controller .
Sign-up for Reduce Measurement System Cost with the New, Rugged CompactDAQ Controller investment picks
MILL VALLEY, Calif.
Sign-up for Redwood Trust Announces Timing For Second Quarter 2014 Earnings Release And Call investment picks
MILL VALLEY, Calif.
Sign-up for Redwood Trust Declares $0.28 Per Share Dividend For The Third Quarter Of 2014 investment picks
MILL VALLEY, Calif.
Sign-up for Redwood Trust Reports Second Quarter 2014 Results investment picks
2014/8/24
SYDNEY--Caltex Australia Ltd.
Sign-up for Refining Loss Weighs on Caltex Result investment picks
2014/8/24
By Ross Kelly SYDNEY--Caltex Australia Ltd.
Sign-up for Refining Loss Weighs on Caltex Result investment picks
ARMONK, N.Y. , Aug.
Sign-up for Reflexis Chooses IBM Cloud Infrastructure To Power Retail Cloud Offering investment picks
Renewable Energy Group, Inc. (NASDAQ:REGI) Chief Financial Officer Chad Stone will become the next chair of the Iowa Biodiesel Board, the Association announced today.
Sign-up for REG CFO Chad Stone Named Chair of Iowa Biodiesel Board investment picks
BASKING RIDGE, N.J. , July 2, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO) , a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that the Data Safety Monitoring Board (DSMB) has initiated an unplanned review of data from the REGULATE-PCI trial.
Sign-up for Regado Announces Initiation Of DSMB Review Of REGULATE-PCI Data investment picks
BASKING RIDGE, N.J. , July 9, 2014 /PRNewswire/ -- Regado Biosciences, Inc., (NASDAQ: RGDO) today announced that, further to their decision to voluntarily pause enrollment in their REGULATE-PCI trial, the United States Food and Drug Administration (FDA) informed the company today that a clinical hold has been placed on all patient enrollment and dosing of either study drug in the ongoing Phase 3 REGULATE-PCI trial.
Sign-up for Regado Biosciences Announces Clinical Hold of REGULATE-PCI Trial Following Voluntary Halt of Trial by Regado investment picks
2014/8/11
Conference Call and Webcast, August 12, 2014, at 8:30 a.m. EDT BASKING RIDGE, N.J. , Aug.
Sign-up for Regado Biosciences Announces Second Quarter 2014 Financial Results and Corporate Highlights investment picks
BASKING RIDGE, N.J. , June 18, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO) , a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit (also known as REG1), its first-in-class, actively controllable injectable antithrombotic drug system, today announced the appointment of Drew Fromkin to the company's Board of Directors.
Sign-up for Regado Biosciences Appoints Pharmaceutical Business Leader Drew Fromkin to Board of Directors investment picks
2014/7/3
NEW YORK (MarketWatch)--Shares of Regado Biosciences (s: rgdo) cratered 39% in premarket trade after the company announced late Wednesday that the Data Safety Monitoring Board initiated an unplanned review of data from a trial of its treatment for blood clots.
Sign-up for Regado Biosciences nearly halved after announcing trial review investment picks
By Michael Calia Regado Biosciences Inc. said Monday that it had terminated the late-stage trial testing of its lead program's efficacy in fighting coronary artery disease, sending the company's shares down 26% in premarket trading.
Sign-up for Regado Biosciences terminates blood-clot drug study investment picks
BASKING RIDGE, N.J. , July 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO) , a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that it will hold a conference call and live audio webcast on Tuesday, Aug.
Sign-up for Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights investment picks
Phase 1 Clinical Data Highlights Factor IXa as an Excellent Target for Anticoagulation Therapy BASKING RIDGE, N.J. , June 23, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO) , a biopharmaceutical company focused on the discovery and development of actively controllable aptamer therapeutics for the acute care setting, today announced the publication in the Journal of Thrombosis and Thrombolysis of data from a single escalating-dose Phase 1 clinical trial of the REG2 anticoagulation system.
Sign-up for Regado Biosciences' REG2 Demonstrates Dose and Concentration-Dependent Suppression of Thrombin Generation investment picks
BELOIT, Wis.
Sign-up for Regal Beloit Corporation Announces Acquisition of Benshaw, Inc. investment picks
BELOIT, Wis.
Sign-up for Regal Beloit Declares Dividend investment picks
KNOXVILLE, Tenn.
Sign-up for Regal Cinemas Partners with Coca-Cola on 'Tweet a Coke' Program investment picks
Regal Entertainment Group (NYSE: RGC), a leading motion picture exhibitor owning and operating the largest theatre circuit in the United States, today announced it will release fiscal second quarter 2014 results on Thursday, July 24, 2014 at 4:00 p.m. Eastern Time and hold a conference call at 4:30 p.m. Eastern Time.
Sign-up for Regal Entertainment Group Announces Timing of Fiscal Second Quarter 2014 Earnings Release and Conference Call investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Redknee Wins Light Reading Leading Lights Inaugural Outstanding OSS/BSS Vendor of the Year Award to Regal Entertainment Group Announces Timing of Fiscal Second Quarter 2014 Earnings Release and Conference Call
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices